Latest Content

  • My Evolving Strategy for Treating Patients With Genotype 3 HCV Infection

    Norah Terrault MD, MPH - 9/10/2015 10 comments / Last Comment: 6/25/2016
    Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
  • Post-EASL Update: Is It Time to Use Resistance Testing to Guide HCV Treatment Decisions?

    Jordan J. Feld MD, MPH - 7/28/2015 5 comments / Last Comment: 12/6/2015
    With the highly effective DAA regimens now available for treating patients with HCV, fewer patients experience treatment failure. Could pretreatment-resistance testing help to decrease failures even further?